Antifungal susceptibility of clinical and environmental isolates of Cryptococcus neoformans to four antifungal drugs determined by two techniques

A total of 64 Cryptococcus neoformans strains, including clinical and environmental Brazilian isolates var. neoformans and var. gattii, were tested for susceptibility to amphotericin B, 5‐flucytosine, fluconazole and itraconazole. The tests were performed according to the recommendations of National Committee of Clinical Laboratory Standards and the method of macrodilution in liquid medium of Shadomy et al. [Manual de Microbiologia Clínica, 4th edn. Buenos Aires: Editorial Medica Panamericana, 1987: 1229–38]. For most drugs there was a significant difference between the readings taken at 24 and 48 h with both methods. When the minimum inhibitory concentrations obtained by the two techniques were compared, significant differences were observed for amphotericin B and fluconazole. Overall, differences in drug susceptibility with respect to the origin of the isolates or the variety of the fungus were not observed. As an exception, the gattii variety exhibited a high resistance rate to amphotericin B when the technique of Shadomy et al. was applied, a fact possibly related to the greater difficulty for treatment of the disease caused by this fungal variety.

[1]  T. Patterson,et al.  Current concepts in Cryptococcosis , 1989, European Journal of Clinical Microbiology and Infectious Diseases.

[2]  M. Ghannoum,et al.  In Vitro Activities of Voriconazole, Fluconazole, and Itraconazole against 566 Clinical Isolates of Cryptococcus neoformans from the United States and Africa , 1999, Antimicrobial Agents and Chemotherapy.

[3]  B. Wanke,et al.  Cryptococcus neoformans var. gattii--evidence for a natural habitat related to decaying wood in a pottery tree hollow. , 1998, Medical mycology.

[4]  J. Martínez-Suárez,et al.  Standardization of antifungal susceptibility testing and clinical relevance. , 1998, Medical mycology.

[5]  F. Dromer,et al.  Antifungal drug resistance in pathogenic fungi. , 1998, Medical mycology.

[6]  J. Perfect,et al.  Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches. , 1997, Drugs.

[7]  S. Franzot,et al.  In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs , 1996, Antimicrobial agents and chemotherapy.

[8]  T. G. Mitchell,et al.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans , 1995, Clinical microbiology reviews.

[9]  D. Dunt,et al.  Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  A. Tunkel,et al.  Therapy of fungal meningitis. , 1995, Clinical neuropharmacology.

[11]  T. Sorrell,et al.  Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  A. Casadevall,et al.  Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole , 1993, Antimicrobial Agents and Chemotherapy.

[13]  M. Ghannoum,et al.  Susceptibility testing of Cryptococcus neoformans: a microdilution technique , 1992, Journal of clinical microbiology.

[14]  M. Pfaller,et al.  Multicenter evaluation of four methods of yeast inoculum preparation , 1988, Journal of clinical microbiology.

[15]  G. Wormser,et al.  In vitro susceptibility of Cryptococcus neoformans isolates from patients with acquired immunodeficiency syndrome. , 1988, Archives of pathology & laboratory medicine.

[16]  Á. Restrepo,et al.  Growth of Paracoccidioides brasiliensis yeast phase in a chemically defined culture medium , 1980, Journal of clinical microbiology.

[17]  W. Merz,et al.  Incidence of polyene-resistant yeasts recovered from clinical specimens , 1980, Antimicrobial Agents and Chemotherapy.